This new data analysis delivers a stunning statistic: 11.4% or 7.1 million children received an ADHD diagnosis. Some 6.5 million children (10.5%) currently live with ADHD. This seems way too much?

From the press release:

An exploration into the national U.S. dataset on children ever diagnosed with ADHD has revealed an “ongoing and ever-expanding” public health issue.

Findings published in the peer-reviewed Journal of Clinical Child & Adolescent Psychology uncover that approximately one million more children, aged 3-17, had received an ADHD diagnosis in 2022 than in 2016.

The paper reveals around one in nine children have ever received an ADHD diagnosis — 11.4%, or 7.1 million children. Some 6.5 million children (10.5%) currently live with ADHD.

Among children currently living with ADHD, 58.1% have moderate or severe ADHD. 77.9% have at least one co-occurring disorder, approximately half of children with current ADHD (53.6%) received ADHD medication, and 44.4% had received behavioral treatment for ADHD in the past year. Nearly one third (30.1%) did not receive any ADHD-specific treatment.

The results follow an analysis of the 2022 National Survey of Children’s Health (NSCH) dataset. They demonstrate that the estimated prevalence of ADHD (based on a parent report) is higher in the United States than comparable estimates from other countries.

The expert team of authors come from institutions including the Centers for Disease Control and Prevention, the Oak Ridge Institute for Science and Education, and the Health Resources and Services Administration.

In the paper, the team explains the increase of ADHD prevalence can partially be explained by “sociodemographic and child characteristics,” whilst they state societal context can also “contribute to the overall trends in the diagnosis of ADHD.” These include the context around children’s mental health before and during the COVID-19 pandemic.

“Public awareness of ADHD has changed over time. ADHD was historically described as an externalizing disorder with a focus on easily observable hyperactive-impulsive symptoms, and was thought to primarily affect boys,” the authors say.

“With increased awareness of symptoms related to attention regulation, ADHD has been increasingly recognized in girls, adolescents, and adults.

“Moreover, ADHD has previously been diagnosed at lower rates among children in some racial and ethnic minority groups. With increased awareness, such gaps in diagnoses have been narrowing or closing.

“Circumstances related to the pandemic may also have increased the likelihood that a child’s ADHD symptoms could cause impairment. For example, in families where children needed to engage in virtual classroom learning while parents were also working from home, previously manageable ADHD symptoms may have become more impairing or symptoms that were previously unobserved by parents may have become recognizable.”

The aim of this new paper was to provide updated U.S. prevalence estimates of diagnosed ADHD; ADHD severity; co-occurring disorders; and receipt of ADHD medication and behavioral treatment.

The team assessed 45,483 completed interviews, monitoring, as well, differences in demographic and clinical subgroups. Questions asked parents for details such as the severity of the condition.

Findings highlight how socioeconomic and geographic factors play a part in diagnosis/prevalence of ADHD.

For example:

• Asian and Hispanic/Latino children had a lower prevalence of diagnosed ADHD than White children.
• Children living in households with high school as the highest level of education and lower-income households had a higher prevalence than children living in households with more education and with income ≥200% of the federal poverty level, respectively.
• Children with public insurance (with or without private insurance) had a higher prevalence than children with private insurance alone.
• Prevalence was also higher for children living in the Northeast, Midwest, or South compared to those living in the West and for children living in rural or suburban areas compared to children living in urban areas.

The results also demonstrated how such factors impacted upon medicated treatment:

• Hispanic children and children living in non-English-speaking households had a lower prevalence of taking ADHD medication than non-Hispanic children and children living in primarily English-speaking homes, respectively.
• A higher prevalence of children with both public and private insurance were taking ADHD medication than children with private insurance only.
• A higher prevalence of children living in the Midwest and South were taking ADHD medication compared to children in the West.

Other behavioral treatments, such as mental health counseling, also followed similar patterns. Explaining the findings further, the authors state: “Shifts in patterns of treatments may also be affected by changes in the demographic distribution of who receives ADHD diagnoses.

“There is evidence that the sex difference for diagnosis of ADHD may be narrowing; in prior years, the ratio of boys to girls diagnosed with ADHD was more than 2:1.”

Concluding, the team state that they hope their findings can be used by clinicians to understand diagnosis and treatment patterns to better inform clinical practice. As well, they hope it could be used by policymakers, government agencies, health care systems, public health practitioners, and other partners to plan for the needs of children with ADHD, such as by ensuring access to care and services for ADHD.

Future research, the team states, could investigate patterns of service delivery during and after the pandemic; as well as modes of ADHD service delivery; uptake and discontinuation of ADHD medication; and receipt of evidence-based behavioral treatment and other recommended services such as school services.

This study is subject to a number of limitations, including it being based on a survey of parent recall and reporting decisions and have not been validated against medical records or clinical judgment.

Abstract of the study:

Objective
To provide updated national prevalence estimates of diagnosed attention-deficit/hyperactivity disorder (ADHD), ADHD severity, co-occurring disorders, and receipt of ADHD medication and behavioral treatment among U.S. children and adolescents by demographic and clinical subgroups using data from the 2022 National Survey of Children’s Health (NSCH).

Method
This study used 2022 NSCH data to estimate the prevalence of ever diagnosed and current ADHD among U.S. children aged 3–17 years. Among children with current ADHD, ADHD severity, presence of current co-occurring disorders, and receipt of medication and behavioral treatment were estimated. Weighted estimates were calculated overall and for demographic and clinical subgroups (n = 45,169).

Results
Approximately 1 in 9 U.S. children have ever received an ADHD diagnosis (11.4%, 7.1 million children) and 10.5% (6.5 million) had current ADHD. Among children with current ADHD, 58.1% had moderate or severe ADHD, 77.9% had at least one co-occurring disorder, approximately half of children with current ADHD (53.6%) received ADHD medication, and 44.4% had received behavioral treatment for ADHD in the past year; nearly one third (30.1%) did not receive any ADHD-specific treatment.

Conclusions
Pediatric ADHD remains an ongoing and expanding public health concern, as approximately 1 million more children had ever received an ADHD diagnosis in 2022 than in 2016. Estimates from the 2022 NSCH provide information on pediatric ADHD during the last full year of the COVID-19 pandemic and can be used by policymakers, government agencies, health care systems, public health practitioners, and other partners to plan for needs of children with ADHD.